CSIMarket
 


Abbott Laboratories  (ABT)
Other Ticker:  
 
 

ABT's Operating Income Growth by Quarter and Year

Abbott Laboratories's Operating Income results by quarter and year




ABT Operating Income (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - 1,304.00 2,378.00 2,432.00
III Quarter September 1,647.00 1,770.00 2,546.00 1,495.00
II Quarter June 1,542.00 2,376.00 1,392.00 672.00
I Quarter March 1,509.00 2,912.00 2,109.00 758.00
FY   4,698.00 8,362.00 8,425.00 5,357.00



ABT Operating Income third quarter 2023 Y/Y Growth Comment
Abbott Laboratories reported decrease in Operating Income in the third quarter 2023 by -6.95% to $ 1,647.00 millions, from the same quarter in 2022.
The decrease in the third quarter 2023 Abbott Laboratories's Operating Income compares unfavorably to the Company's average Operating Income increase of 11.64%.

Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 9 other companies have achieved higher Operating Income growth. While Abbott Laboratories' s Operating Income decline of -6.95% ranks overall at the positon no. 706 in the third quarter 2023.

Explain Operating Income growth


ABT Operating Income ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - -45.16 % -2.22 % 75.09 %
III Quarter September -6.95 % -30.48 % 70.3 % 24.79 %
II Quarter June -35.1 % 70.69 % 107.14 % -44.28 %
I Quarter March -48.18 % 38.07 % 178.23 % 2.57 %
FY   - -0.75 % 57.27 % 18.2 %

Financial Statements
Abbott Laboratories's third quarter 2023 Operating Income $ 1,647.00 millions ABT's Income Statement
Abbott Laboratories's third quarter 2022 Operating Income $ 1,770.00 millions Quarterly ABT's Income Statement
New: More ABT's historic Operating Income Growth >>


ABT Operating Income (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - -26.33 % -6.6 % 62.68 %
III Quarter September 6.81 % -25.51 % 82.9 % 122.47 %
II Quarter June 2.19 % -18.41 % -34 % -11.35 %
I Quarter March 15.72 % 22.46 % -13.28 % -45.43 %
FY (Year on Year)   - -0.75 % 57.27 % 18.2 %




Operating Income third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #10
Healthcare Sector #39
Overall #706

Operating Income Y/Y Growth Statistics
High Average Low
157.45 % 11.64 % -65.4 %
(March 31, 2008)   (March 31, 2014)
Operating Income third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #10
Healthcare Sector #39
Overall #706
Operating Income Y/Y Growth Statistics
High Average Low
157.45 % 11.64 % -65.4 %
(March 31, 2008)   (March 31, 2014)

Operating Income by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Abbott Laboratories's Q/Q Operating Income Growth


Operating Income Q/Q Growth Statistics
High Average Low
313.29 % 12.39 % -75.54 %
(June 30. 2012)  


ABT's III. Quarter Q/Q Operating Income Comment
Abbott Laboratories achieved in the III. Quarter 2023 below company average Operating Income increase of 6.81% quarter on quarter, to $ 1,647.00 millions.

III. Quarter 2023 performance were paradoxical, even if beneath the regular, yet it demonstrates a quite recovery measured to the -25.51% in the same quarter a year ago Filipe Silva, an industry consultant situated in London mentioned.

Within Major Pharmaceutical Preparations industry 12 other companies have achieved higher Operating Income quarter on quarter growth. While Abbott Laboratories's Operating Income growth quarter on quarter, overall rank is 816.


Operating Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #13
Healthcare Sector #55
Overall #816
Operating Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #13
Healthcare Sector #55
Overall #816
Operating Income Q/Q Growth Statistics
High Average Low
313.29 % 12.39 % -75.54 %
(June 30. 2012)  


ABT's III. Quarter Q/Q Operating Income Comment
Abbott Laboratories achieved in the III. Quarter 2023 below company average Operating Income increase of 6.81% quarter on quarter, to $ 1,647.00 millions.

III. Quarter 2023 ABT's Operating Income quarter on quarter growth were a mixed bag, although beneath the regular, yet it demonstrates a quite acceleration compare to the -25.51% in the same quarter a year ago Filipe Silva, an industry consultant situated in London mentioned.

Within Major Pharmaceutical Preparations industry 12 other companies have achieved higher Operating Income quarter on quarter growth. While Abbott Laboratories's Operating Income growth quarter on quarter, overall rank is 816.


Abbott Laboratories's 12 Months Operating Income Growth Year on Year


Operating Income TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Operating Income 12 Months Ending $ 6,002.00 $ 6,125.00 $ 6,959.00 $ 8,362.00 $ 9,436.00
Y / Y Operating Income Growth (TTM) -36.39 % -40.02 % -24.59 % -0.75 % 11.29 %
Year on Year Operating Income Growth Overall Ranking # 802 # 504 # 339 # 302 # 730
Seqeuential Operating Income Change (TTM) -2.01 % -11.98 % -16.78 % -11.38 % -7.6 %
Seq. Operating Income Growth (TTM) Overall Ranking # 1216 # 891 # 627 # 1068 # 1278




Cumulative Operating Income growth Comment
Abbott Laboratories showed decline, but improvement compare to trailing twelve month Operating Income decrease in Jun 30 2023. If the fiscal year would end in Sep 30 2023, Abbott Laboratories's annual Operating Income decrease would be -36.39% year on year to $6,002 millions.

In the Healthcare sector 44 other companies have achieved higher trailing twelve month Operating Income growth. While Operating Income growth total ranking has deteriorated compare to previous quarter from 504 to 802.

Operating Income TTM Q/Q Growth Statistics
High Average Low
157.45 %
11.64 %
-65.4 %
 

Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 16
Healthcare Sector # 45
Overall # 802

Operating Income TTM Y/Y Growth Statistics
High Average Low
157.45 %
11.64 %
-65.4 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 16
Sector # 67
S&P 500 # 1216
Cumulative Operating Income growth Comment
Abbott Laboratories showed decline, but improvement compare to trailing twelve month Operating Income decrease in Jun 30 2023. If the fiscal year would end in Sep 30 2023, Abbott Laboratories's annual Operating Income drop would be -36.39% year on year to $6,002 millions.

In the Healthcare sector 44 other companies have achieved higher trailing twelve month Operating Income growth. While Operating Income growth total ranking has deteriorated compare to previous quarter from 504 to 802.

Operating Income TTM Q/Q Growth Statistics
High Average Low
157.45 %
11.64 %
-65.4 %
 


Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 16
Healthcare Sector # 45
Overall # 802

Operating Income TTM Y/Y Growth Statistics
High Average Low
157.45 %
11.64 %
-65.4 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 16
Sector # 67
S&P 500 # 1216




Other Operating Income Growth
Major Pharmaceutical Preparations Industry Operating Income Growth Trends and Statistics
Healthcare Sector Operating Income Growth Statistics
Operating Income Growth Trends for overall market
ABT's Operating Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Operating Income Growth
Lowest Ranking Operating Income Growth
Operating Income Growth for ABT's Competitors
Operating Income Growth for Abbott Laboratories's Suppliers
Operating Income Growth for ABT's Customers

You may also want to know
ABT's Annual Growth Rates ABT's Profitability Ratios ABT's Asset Turnover Ratio ABT's Dividend Growth
ABT's Roe ABT's Valuation Ratios ABT's Financial Strength Ratios ABT's Dividend Payout Ratio
ABT's Roa ABT's Inventory Turnover Ratio ABT's Growth Rates ABT's Dividend Comparisons



Companies with similar Operating Income drop for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Operating Income for the quarter ending Sep 30 2023
Bio techne Corp-0.81%$ -0.808 millions
The Pennant Group Inc -1.16%$ -1.162 millions
Bio rad Laboratories Inc -1.99%$ -1.990 millions
Corcept Therapeutics Inc-2.37%$ -2.371 millions
Mettler Toledo International Inc-3.07%$ -3.068 millions
Tenet Healthcare Corp-4.70%$ -4.698 millions
West Pharmaceutical Services Inc -4.78%$ -4.780 millions
Bruker Corporation-5.18%$ -5.179 millions
Henry Schein Inc -5.21%$ -5.213 millions
Hologic Inc-5.96%$ -5.962 millions
Sonida Senior Living Inc -6.27%$ -6.269 millions
Abbott Laboratories-6.95%$ -6.949 millions
Gilead Sciences Inc -7.54%$ -7.543 millions
Vertex Pharmaceuticals Inc-7.86%$ -7.864 millions
Bristol myers Squibb Company-9.18%$ -9.183 millions
Regeneron Pharmaceuticals Inc -9.21%$ -9.210 millions
National Research Corporation-10.39%$ -10.388 millions
Quest Diagnostics Inc-12.76%$ -12.755 millions
Bausch and Lomb Corp-13.04%$ -13.043 millions
Carlisle Companies Incorporated-13.87%$ -13.871 millions
Pediatrix Medical Group Inc -15.01%$ -15.015 millions
Community Health Systems Inc -15.20%$ -15.196 millions
Teva Pharmaceutical Industries Limited-15.27%$ -15.274 millions
Zynex inc -16.36%$ -16.362 millions
Entera Bio Ltd -16.72%$ -16.719 millions
Pacira Biosciences inc -16.76%$ -16.760 millions
Viatris Inc -19.35%$ -19.354 millions
Royalty Pharma Plc-21.21%$ -21.210 millions
Luna Innovations Inc-22.06%$ -22.057 millions
Avantor Inc -23.79%$ -23.785 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com